Tamoxifen 20 - British Dragon

Developed in 1962 by ICI, Tamoxifen citrate shifted from contraceptive research into cancer therapy after studies showed it could block estrogen receptors in breast tissue. It entered large-scale clinical trials in the 1970s and was approved for medical use in 1977 under the trade name Nolvadex. It quickly became a foundational drug in estrogen receptor-positive breast cancer treatment. In the 1980s and beyond, its role expanded as athletes and bodybuilders began using it off-label to mitigate estrogenic effects caused by anabolic steroids.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Tamoxifen 20 by British Dragon, consult with your doctor or healthcare professional.